- The deal would be for $4.9 billion
- It will add to its portfolio of oncology drugs
On Monday, Gilead Sciences Inc said it would buy Forty Seven Inc. It will be $4.9 billion in cash. To its portfolio of oncology drugs, it will add an experimental treatment that targets blood cancer.
A 62% jump was observed for the Shares of Forty Seven. It traded slightl....
Tags : Merger and Acquisition ,